serrao6

March 2021: KYW InDepth Podcast – Vaccines are just part of the battle. Good therapeutics are needed to fight COVID-19 as well.

Most of the attention right now is on vaccines, but vaccines are only part of the battle against COVID-19. Dr. Mark DiNubile, Chief Medical Officer at BioAegis, joins KYW Newsradio In Depth to talk about what’s out there right now, the science behind COVID-19 treatments, and why he believes so strongly that gelsolin therapy can …

March 2021: KYW InDepth Podcast – Vaccines are just part of the battle. Good therapeutics are needed to fight COVID-19 as well. Read More »

February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity

MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported that low levels of gelsolin are associated with severity and organ …

February 2021: NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity Read More »

November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator

No drug-related safety signals identified by the independent Data and Safety Monitoring Board. MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced that it has expanded its clinical trial in severe COVID-19 …

November 2020: BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator Read More »

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

The leadership team of BioAegis Therapeutics will share their experiences this year as they reframed their strategy to address the COVID-19 threat to their employees and hustled to initiate a COVID-19 clinical trial for severe COVID-19 patients. When: Thursday, August 20, 2020 12:00 p.m. – 1:00 p.m. EDT Where: Online (GoToWebinar) Contact: WIB-Metro New York …

August 20, 2020: WIB-Metro New York – Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience Read More »

June 5, 2020: BioNJ COVID-19 Rapid Fire Research Showcase

BioAegis has been selected as a featured company in the upcoming BioNJ COVID-19 Rapid Fire Research Showcase.  Our Chief Executive Officer and Co-founder, Dr. Susan Levinson, will present our goundbreaking recombinant human plasma gelsolin (rhu-pGSN) therapy. WHEN:    Friday, June 5, 2020, 9:00 a.m. – 10:00 a.m. Register Now

Partnership/Capital Advisor, Richard Barno

Mr. Barno is a Capital Advisor and Technology Entrepreneur, and former Executive at Xerox Corporation, IBM, and Institutional Portfolio Manager at UBS Paine Webber.  He has advised many Fortune 500 companies including Centel, Hartford Group, Apple Computer, IBM, Microsoft, Boeing, and for the Government of Canada.  He founded Press Access ( acquired by Lexis-Nexis) and …

Partnership/Capital Advisor, Richard Barno Read More »

VP, Corporate Development and Communications, Steven Cordovano

Steven Cordovano brings to BioAegis a sophisticated market perspective and broad investor network gained through years of investment experience as a highly successful fund manager. He has worked in finance and portfolio management for 25 years. Prior to BioAegis, Mr. Cordovano was a Partner with Trivalent Partners, where he assisted emerging growth companies in developing …

VP, Corporate Development and Communications, Steven Cordovano Read More »

John Stossel

Nineteen-time Emmy-winner John Stossel was hailed by The Dallas Morning News as “the most consistently thought-provoking TV reporter of our time.”  Stossel began his career as a business-bashing consumer reporter calling for government regulation. But when he saw that regulation causes new problems, he woke up and started reporting on wonderful things that free markets …

John Stossel Read More »

Chief Medical Officer, Mark J. DiNubile, MD, FIDSA

Mark J. DiNubile, MD FIDSA, has recently joined BioAegis Therapeutics as our Chief Medical Officer to propel us forward into late-stage clinical development. He brings to the table the rare combination of clinical and research expertise along with broad pharmaceutical industry experience, coupled with his long-standing dedication to elucidating the clinical utility of plasma gelsolin. …

Chief Medical Officer, Mark J. DiNubile, MD, FIDSA Read More »